Combined detection of biomarkers such as MUC5AC and DUPAN-2 can improve the limitations of false negatives of CA19–9 in Lewis-negative individuals (49), while the combined detection of CEA and CA125 aids in the differential diagnosis of pancreatic cancer and other gastrointestinal tumors (50, 51). Here, CEACAM5 is linked to digestive system neoplasm.